- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07232069
Prospectieve Gerandomiseerde Evaluatie en Behandeling van Premature Atherosclerose (PRE-EMPT) (PRE-EMPT)
Prospectieve Gerandomiseerde Evaluatie en Behandeling van Premature Atherosclerose
Heart disease is the leading cause of death for men, women, and people of most racial and ethnic groups in the United States. This clinical trial will test if screening and early treatment of mild heart disease works.
PRE-EMPT will screen individuals at low 10-year risk of heart disease with heart disease risk factors to identify those who already have early cholesterol build up, also called "plaque", in their heart arteries. It consists of two phases:
-
A Screening Study - Participants will be assessed for plaque by one or both of these scans.
- Coronary Artery Calcium (CAC) Scan: A CT scan that looks for calcium or plaque in heart arteries.
- Coronary CT Angiography (CCTA) Scan: A CT scan that uses contrast dye to create detailed 3D pictures of heart arteries to look for plaque.
-
A Treatment Trial (approximately 1,500 participants) - Based on the results of the CCTA, participants may be randomized into a two-year trial to test medications aimed at reducing or stabilizing plaque. Participants will have a 1 in 4 chance of receiving only placebo, and a 3 in 4 chance of receiving at least one active medication. Participants will take two pills once a day-either both active medications, one active and one placebo, or both placebos.
- Rosuvastatin 20 mg: a cholesterol-lowering medicine
- Colchicine 0.5 mg: a medication that lowers inflammation
Everyone in the trial will be given information and advice on heart-healthy diet and lifestyle.
Participants will have up to two in-person visits for the screening study, then phone visits for the Treatment Trial at the beginning, 3 months, 12 months and 24 months when they will also have an in-person visit for a CCTA Scan. Participants will have blood drawn using an at-home collection device mailed to their home at the beginning, 3 months, and end of the study.
Studie Overzicht
Toestand
Conditie
Gedetailleerde beschrijving
The PRE-EMPT trial will be a 2x2 factorial, double-masked, placebo-controlled randomized trial of the effects of high-intensity statin and low-dose colchicine, alone and in combination, on CCTA-defined Non-Calcified Coronary Plaque (NCCP) volume at 2 years. Participants found through the screening study with CAC 1-99, or through the known plaque pathway, will be eligible for the trial if they have NCCP without severe stenosis or any other exclusion criteria. Study drug will be delivered directly to participants' homes, lab samples will be self-collected at home, and all study visits will be virtual except the imaging visits (up to 3 over 2 years). The only in-person study activities will be the CAC scan, if applicable, and CCTA at baseline and 2 years. The investigators anticipate that this approach will be attractive to middle-aged, busy individuals who are otherwise healthy and asymptomatic. Importantly, all participants in PRE-EMPT will receive an mHealth lifestyle intervention designed to support behavioral modification, ensuring that all individuals benefit from evidence-based strategies for cardiovascular risk reduction.
Studietype
Inschrijving (Geschat)
Fase
- Fase 3
Contacten en locaties
Studiecontact
- Naam: Rachel Olson, Project Manager
- Telefoonnummer: 919-309-5544
- E-mail: rachel.e.olson@duke.edu
Studie Locaties
-
-
Alabama
-
Birmingham, Alabama, Verenigde Staten, 35205
- Werving
- University of Alabama at Birmingham
-
Hoofdonderzoeker:
- Kevin Riggs, MD
-
Contact:
- Dalton Norwood
- Telefoonnummer: 909-786-8315
- E-mail: daltonnorwood@uabmc.edu
-
Mobile, Alabama, Verenigde Staten, 36608
- Werving
- Cardiology Associates
-
Contact:
- Lynn Ward, RN BSN CCRC
- Telefoonnummer: 251-607-9797
- E-mail: lynnward@cardassoc.com
-
Hoofdonderzoeker:
- Jason Cole, MD
-
-
California
-
Los Angeles, California, Verenigde Staten, 90095
- Werving
- University of California, Los Angeles
-
Contact:
- Lynae Edmunds
- Telefoonnummer: 310--210-9806
- E-mail: laedmunds@mednet.ucla.edu
-
Hoofdonderzoeker:
- Karol Watson, MD
-
Los Angeles, California, Verenigde Staten, 90502
- Werving
- Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center
-
Contact:
- Sajad Hamal
- Telefoonnummer: 310-974-9336
- E-mail: shamal@lundquist.org
-
Hoofdonderzoeker:
- Matthew Budoff, MD
-
-
Georgia
-
Hiram, Georgia, Verenigde Staten, 30141
- Werving
- Wellstar Kennestone Hospital
-
Hoofdonderzoeker:
- Frank Corrigan, MD
-
Contact:
- Frank Corrigan, MD
- Telefoonnummer: 678-324-4444
- E-mail: frank.corrigan@wellstar.org
-
-
Illinois
-
Chicago, Illinois, Verenigde Staten, 60637
- Werving
- University of Chicago
-
Hoofdonderzoeker:
- Tamar Polonsky, MD
-
Contact:
- Tamar Polonsky, MD
- Telefoonnummer: 773-702-1409
- E-mail: tpolonsky@bsd.uchicago.edu
-
-
Maryland
-
Baltimore, Maryland, Verenigde Staten, 21287
- Nog niet aan het werven
- Johns Hopkins University
-
Contact:
- Prati Pratishruti, MBBS
- Telefoonnummer: 410-301-1245
- E-mail: fpratis1@jhu.edu
-
Hoofdonderzoeker:
- Michael Blaha, MD
-
-
Massachusetts
-
Boston, Massachusetts, Verenigde Staten, 02114
- Werving
- Massachusetts General Hospital Brigham
-
Contact:
- Pearl Lee, MSc
- Telefoonnummer: 617-721-7783
- E-mail: plee23@mgh.harvard.edu
-
Hoofdonderzoeker:
- Michael Honigberg, MD
-
-
Minnesota
-
Duluth, Minnesota, Verenigde Staten, 55805
- Werving
- Essentia Health
-
Contact:
- Martha Vanderlinde, BS
- Telefoonnummer: 218-786-2729
- E-mail: Martha.Vanderlinde@essentiahealth.org
-
Hoofdonderzoeker:
- Catherine Benzinger, MD
-
-
New York
-
Mount Kisco, New York, Verenigde Staten, 10549
- Nog niet aan het werven
- Northern Westchester Hospital
-
Contact:
- Dina Katz, MD
- Telefoonnummer: 914-762-5810
- E-mail: PRE-EMPT@northwell.edu
-
Hoofdonderzoeker:
- Dina Katz, MD
-
New York, New York, Verenigde Staten, 10021
- Werving
- Weill Cornell Medicine
-
Contact:
- Dolores Reynolds, RN
- Telefoonnummer: 212-746-4617
- E-mail: dtr2001@med.cornell.edu
-
Hoofdonderzoeker:
- Sam Kim, MD
-
New York, New York, Verenigde Staten, 10016
- Werving
- New York University Langone
-
Hoofdonderzoeker:
- Harmony Reynolds, MD
-
Contact:
- Harmony Reynolds, MD
- Telefoonnummer: 212-263-4320
- E-mail: PREEMPT@nyulangone.org
-
-
North Carolina
-
Durham, North Carolina, Verenigde Staten, 27710
- Werving
- Duke University Hospital
-
Hoofdonderzoeker:
- Nishant Shah, MD
-
Contact:
- Niki Huffman
- Telefoonnummer: 919-681-6458
- E-mail: niki.huffman@duke.edu
-
Winston-Salem, North Carolina, Verenigde Staten, 27157
- Werving
- Wake Forest University, Advocate Health
-
Hoofdonderzoeker:
- Michael Shapiro, MD
-
Contact:
- Sophia Dawson, BA
- Telefoonnummer: 336-713-2338
- E-mail: Sophia.Dawson@advocatehealth.org
-
-
Oregon
-
Portland, Oregon, Verenigde Staten, 97239
- Nog niet aan het werven
- Oregon Health and Sciences University
-
Contact:
- John Halvorson
- Telefoonnummer: 503-418-1679
- E-mail: halvorsj@ohsu.edu
-
Hoofdonderzoeker:
- Maros Ferencik, MD
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Verenigde Staten, 19107
- Nog niet aan het werven
- Thomas Jefferson University
-
Contact:
- Caroline Freeman, BS
- Telefoonnummer: 215-792-3872
- E-mail: Caroline.Freeman@Jefferson.edu
-
Hoofdonderzoeker:
- Chris Chambers, MD
-
Pittsburgh, Pennsylvania, Verenigde Staten, 15213
- Werving
- University of Pittsburgh Medical Center
-
Hoofdonderzoeker:
- Anum Saeed, MD
-
Contact:
- Karli Drewencki
- Telefoonnummer: 412-647-2931
- E-mail: drewenckikr2@upmc.edu
-
-
South Carolina
-
Charleston, South Carolina, Verenigde Staten, 29425
- Werving
- Medical University of South Carolina (MUSC)
-
Hoofdonderzoeker:
- Sheldon Litwin, MD
-
Contact:
- Melissa Amitrano, MPH
- Telefoonnummer: 843-876-5009
- E-mail: amitrano@musc.edu
-
-
Tennessee
-
Nashville, Tennessee, Verenigde Staten, 37203
- Nog niet aan het werven
- Vanderbilt University
-
Hoofdonderzoeker:
- Deepak Gupta, MD
-
Contact:
- Gabriella Davies Thoppil, MD MPH
- Telefoonnummer: 615-421-1143
- E-mail: g.thoppil@vumc.org
-
-
Texas
-
Houston, Texas, Verenigde Staten, 77030
- Werving
- Houston Methodist Hospital
-
Contact:
- Peyton Martin
- Telefoonnummer: 443-413-6350
- E-mail: knasir@houstonmethodist.org
-
Hoofdonderzoeker:
- Khurrrram Nasir, MD
-
-
Virginia
-
Charlottesville, Virginia, Verenigde Staten, 22903
- Werving
- University of Virginia (UVA)
-
Contact:
- James Ingersoll
- Telefoonnummer: 434-982-1058
- E-mail: WFC5KC@uvahealth.org
-
Hoofdonderzoeker:
- Todd Villines, MD
-
Fairfax, Virginia, Verenigde Staten, 22031
- Nog niet aan het werven
- Inova Health System
-
Contact:
- Mahira Awan
- Telefoonnummer: 571-472-8570
- E-mail: mahira.awan@inova.org
-
Hoofdonderzoeker:
- Jared Spitz, MD
-
-
Wisconsin
-
Marshfield, Wisconsin, Verenigde Staten, 54449
- Werving
- Marshfield Clinical Research Institute
-
Contact:
- Kelly Scheffen
- Telefoonnummer: 715-221-7285
- E-mail: preempt@marshfieldresearch.org
-
Hoofdonderzoeker:
- Jeff VanWormer
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Women aged 40-60 years; Men aged 30-50 years
- Willing and able to provide informed consent and comply with study procedures
- Smart phone user
- Use of highly effective contraception by females with reproductive potential.
- CAC score 1-99 in the screening study or entry through the known plaque pathway (with mild CAC or CAC<100 if known; elevated CAC on baseline CCTA is not exclusionary in the known plaque arm)
- Diagnostic baseline CCTA with NCPV ≥10 mm3 as assessed by the central core lab
Exclusion Criteria:
- Clinical diagnosis of ASCVD including coronary artery disease (CAD), peripheral arterial disease (PAD) or cerebrovascular disease (CeVD)
- Current symptoms thought to be from CAD
- PREVENT ASCVD 10-year risk ≥5% (if known)
- Diabetes Mellitus (DM) as defined by any of the following: DM diagnosis in the medical record or HbA1C of 6.5% or greater. (if known)
- LDL-C ≥190mg/dL (most recent, if known)
- HIV (if known)
- Severe liver disease or untreated Hepatitis C infection (if known)
- Pregnancy, lactation or intending to become pregnant during the study period of 2 years
- eGFR <45mL/min/1.73m2 (if known)
- AST or ALT >1.5x the upper limit of normal (if known)
- BMI>40kg/m2 or unable to have a CCTA scan for any reason
- Allergy to iodinated intravenous contrast or other contraindication to CCTA
- Current or previous use of lipid lowering therapy or colchicine
- Known allergic reactions or sensitivity to the study intervention(s), including known intolerance or contraindication(s) to statin or colchicine, or long-term use of medications that are contraindicated with colchicine or rosuvastatin.
- Systemic cancer undergoing active treatment
- PREVENT ASCVD 10-year risk ≥5%
- eGFR <45 ml/min/1.73m2 per baseline labs, (2021 CKD-EPI equation will be used if multiple options are available)
- Hemoglobin A1c ≥6.5% per baseline labs
- LDL-C ≥190mg/dL per baseline labs
- Severe proximal coronary artery stenosis as determined by the central core lab (≥50% left main or ≥70% proximal major coronary artery stenosis)
- Known contraindication to follow-up CCTA (e.g., new IV contrast allergy discovered during the baseline CCTA)
- Individuals who are excluded based on any of these factors will be notified as to the reason for exclusion and encouraged to follow-up locally to address this medical issue with their treating physician.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Preventie
- Toewijzing: Gerandomiseerd
- Interventioneel model: Faculteitstoewijzing
- Masker: Verviervoudigen
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: rosuvastatin 20mg plus colchicine-matched placebo
statin plus placebo (two pills once daily) |
Statin
Andere namen:
Placebo, non-active, drug-matched |
|
Experimenteel: colchicine 0.5mg plus rosuvastatin-matched placebo
anti-inflammatory plus placebo (two pills once daily) |
Placebo, non-active, drug-matched Anti-inflammatory
Andere namen:
|
|
Experimenteel: rosuvastatin 20mg plus colchicine 0.5mg
statin plus anti-inflammatory (two pills once daily) |
Statin
Andere namen:
Anti-inflammatory
Andere namen:
|
|
Placebo-vergelijker: placebo plus placebo
Placebo and placebo (two pills once daily) |
Placebo, non-active, drug-matched |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Non-calcified plaque volume (NCPV) on CCTA at 2 years, adjusted for baseline NCPV.
Tijdsspanne: 2 years
|
Plaque volume in mm3 in each group |
2 years
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Verandering in LDL-C (low-density lipoproteïne cholesterol)
Tijdsspanne: Vanaf de baseline tot 2 jaar
|
Vanaf de baseline tot 2 jaar
|
|
|
Verandering in non-HDL-C (high-density lipoproteïne cholesterol)
Tijdsspanne: Baseline tot 2 jaar
|
Baseline tot 2 jaar
|
|
|
Number of participants with Drug Discontinuation
Tijdsspanne: Up to 2 years
|
Drug Tolerability outcome |
Up to 2 years
|
|
Overall drug treatment adherence
Tijdsspanne: Up to 2 years
|
Number of days on study drugs |
Up to 2 years
|
|
Safety events of special interest
Tijdsspanne: Up to 2 years
|
Number of safety events of special interest per group |
Up to 2 years
|
|
Total plaque volume
Tijdsspanne: Up to 2 years
|
Plaque volume in mm3 per group |
Up to 2 years
|
|
Low-attenuation plaque volume
Tijdsspanne: Up to 2 years
|
Low attenuated plaque volume in mm3 per group |
Up to 2 years
|
|
Calcified plaque volume
Tijdsspanne: Up to 2 years
|
Calcified plaque volume in mm3 per group |
Up to 2 years
|
|
Number of participants with stenosis
Tijdsspanne: Up to 2 years
|
Number of participants with stenosis per group |
Up to 2 years
|
|
Segment involvement score
Tijdsspanne: Up to 2 years
|
Average score per group |
Up to 2 years
|
|
Number of participants with qualitative calcified, partially calcified and non-calcified plaque composition
Tijdsspanne: Up to 2 years
|
Number of participants with each plaque composition description per group |
Up to 2 years
|
|
Number of participants with High-risk plaque features (positive remodeling, spotty calcium, napkin ring sign)
Tijdsspanne: Up to 2 years
|
Number of participants with each plaque feature (high-risk) per group |
Up to 2 years
|
Medewerkers en onderzoekers
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Zwavelverbindingen
- Organische chemicaliën
- Heterocyclische verbindingen, 1-ring
- Heterocyclische verbindingen
- Farmaceutische voorbereidingen
- Doseringsvormen
- Koolwaterstoffen
- Alkaloïden
- Amides
- Pyrimidines
- Koolwaterstoffen, gehalogeneerd
- Sulfonamides
- Sulfonen
- Fluorobenzenes
- Koolwaterstoffen, gefluoreerd
- Rosuvastatine Calcium
- Colchicine
- Tabletten
Andere studie-ID-nummers
- Pro00118744
- UG3HL181434 (Subsidie/contract van de Amerikaanse NIH)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .